On August 1, 2022 Ipsen (Euronext: IPN; ADR: IPSEY) and AGV Discovery reported that Ipsen has exercised its option to acquire exclusive worldwide rights to an investigational ERK inhibitor, discovered by AGV Discovery (Press release, Ipsen, AUG 1, 2022, View Source [SID1234617185]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The decision follows the successful achievement of a key developmental milestone and is the result of a research collaboration and option agreement between the companies, established in September 2020.

"We were encouraged by the early pre-clinical data and are excited to support the ongoing development of this promising therapeutic candidate", said Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development (REED) at Ipsen. "We look forward to advancing the science that we hope can one day deliver new, innovative treatments for cancer patients with high unmet needs across a range of different tumor types."

Cédric BORIES, President, AGV Discovery commented, "I am happy and proud to officially extend our collaboration with Ipsen. It represents a great opportunity to demonstrate our capabilities and have our asset grow, under the guidance of this innovative pharmaceutical company".